Drug Trial Radar · NCT06395948
A Study Evaluating APG777 in Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
470
Actual
Start
Apr 29, 2024
Primary completion
Nov 2026
Study completion Jun 2028
Sponsor
- Lead sponsor
- Apogee Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.
Conditions
- Atopic Dermatitis
Interventions
APG777Drug
APG777 subcutaneous injection
PlaceboDrug
Matching placebo subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI)Time frame: Baseline and at Week 16
- Part B: Proportion of participants who achieve EASI 75 at Week 16Time frame: At Week 16
Locations
94 sites in 9 countries. Site status is shown where the registry gives one.
Investigational Site
Fountain Valley, California
Investigational Site
Los Angeles, California
Investigational Site
San Diego, California
Investigational Site
New Haven, Connecticut
Investigational Site
Coral Gables, Florida
Investigational Site
Jacksonville, Florida
Investigational Site
Margate, Florida
Investigational Site
Douglasville, Georgia
Investigational Site
Chicago, Illinois
Investigational Site
Skokie, Illinois
Investigational Site
West Lafayette, Indiana
Investigational Site
Bowling Green, Kentucky
Investigational Site
Rockville, Maryland
Investigational Site
Detroit, Michigan
Investigational Site
Troy, Michigan
Investigational Site
Portsmouth, New Hampshire
Investigational Site
New York, New York
Investigational Site
Wilmington, North Carolina
Investigational Site
Boardman, Ohio
Investigational Site
Mason, Ohio
Investigational Site
Portland, Oregon
Investigational Site
Pittsburgh, Pennsylvania
Investigational Site
Charleston, South Carolina
Investigational Site
Nashville, Tennessee
Investigational Site
Dallas, Texas
Investigational Site
Dallas, Texas
Investigational Site
San Antonio, Texas
Investigational Site
Norfolk, Virginia
Investigational Site
Mill Creek, Washington
Investigational Site
Calgary, Alberta, Canada
Investigational Site
Calgary, Alberta, Canada
Investigational Site
Edmonton, Alberta, Canada
Investigational Site
Vancouver, British Columbia, Canada
Investigational Site
Winnipeg, Manitoba, Canada
Investigational Site
Fredericton, New Brunswick, Canada
Investigational Site
Ajax, Ontario, Canada
Investigational Site
Markham, Ontario, Canada
Investigational Site
Mississauga, Ontario, Canada
Investigational Site
Ottawa, Ontario, Canada
Investigational Site
Peterborough, Ontario, Canada
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.